Search
Recce is developing antibiotics which target bacteria, including their superbug forms, in humans.

Melrose's Recce begins trading

Bentley-based biotech company Recce has popped the cork on its first day of trading on the ASX, following completion of a $5 million initial public offering.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Recce (RCE)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/08/18

1 year TSR5 year TSR
40thElsight237%0%
315thRecce16%0%
638thNorwood Systems-33%0%
675thCFOAM-39%0%
737 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

09/03/17
$20k Sold
16/01/17
$0 Bought
16/01/17
$0 Other
Total value as at the date of the transaction
Source: Morningstar

Revenue

151st↑CFOAM$1.4m
152nd↑Recce$1.3m
154th↓Norwood Systems$1.3m
155th-Elsight$1.2m
237 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer